Figure S8 from CD46-Targeted Theranostics for PET and ²²⁵Ac-Radiopharmaceutical Therapy of Multiple Myeloma

Anju Wadhwa; Sinan Wang; Bonell Patiño-Escobar; Anil P. Bidkar; Kondapa Naidu Bobba; Emily Chan; Niranjan Meher; Scott Bidlingmaier; Yang Su; Suchi Dhrona; Huimin Geng; Vishesh Sarin; Henry F. VanBrocklin; David M. Wilson; Jiang He; Li Zhang; Veronica Steri; Sandy W. Wong; Thomas G. Martin; Youngho Seo; Bin Liu; Arun P. Wiita; Robert R. Flavell

doi:10.1158/1078-0432.25324388

Abstract

Figure S8: Bioluminescence Images of NSG mouse showed an increase in tumor burden gradually injected with different doses of [225Ac]Ac-DOTA-YS5 from each group and saline group.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wadhwa et al. (2024) studied this question.

synapsesocial.com/papers/68e76734b6db6435876dca72 https://doi.org/10.1158/1078-0432.25324388

View Full Paper

Ask AI

Bookmark

Share

Figure S8 from CD46-Targeted Theranostics for PET and ²²⁵Ac-Radiopharmaceutical Therapy of Multiple Myeloma

Abstract

Discussion

Cite This Study

Figure S8 from CD46-Targeted Theranostics for PET and ²²⁵Ac-Radiopharmaceutical Therapy of Multiple Myeloma

Abstract

Discussion

Cite This Study

Keep reading

Keep reading